Phenoplex™
25844 Phenoplex™ spatial analysis of whole-slide colon adenocarcinoma imaged with Orion™ 13-plex one-round staining and imaging
Resources / Phenoplex™ spatial analysis of whole-slide colon adenocarcinoma imaged with Orion™ 13-plex one-round staining and imaging
Phenoplex™
Phenoplex™ spatial analysis of whole-slide colon adenocarcinoma imaged with Orion™ 13-plex one-round staining and imaging
Presented at AACR 2025
Description

The ability to image tissue microenvironments (TME) at high-plex over an entire slide without requiring multiple staining steps allows for unprecedented insights into tissue architecture and the molecular mechanisms of immune and disease processes. Here we investigate a whole slide tissue section of high-grade colon adenocarcinoma, a hot tumor that contains prominent clusters of PD-L1 expression scattered throughout, using single-step high-plex staining and imaging at single-cell resolution followed by the analysis of single-cell phenotypes, tissue segmentation and spatial proximity and nearest neighbor analysis.

Authors and institutions

Fabian Schneider1, James Mansfield1, Edward Lo2, Tad George2, Joshua Nordberg2

  1. Visiopharm A/S, Horsholm, Denmark
  2. RareCyte, Seattle, WA
Questions? We’re here to help.
Contact us
Categories: 26729 Spatial analysis of the DLBCL tumor microenvironment via the novel SignalStar®multiplex immunohistochemistry assay
Resources / Spatial analysis of the DLBCL tumor microenvironment via the novel SignalStar®multiplex immunohistochemistry assay
Phenoplex™
Spatial analysis of the DLBCL tumor microenvironment via the novel SignalStar® multiplex immunohistochemistry assay
Originally presented at AACR 2025
Description

Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, accounting for more than 18,000 cases each year within the United States. While roughly 60% of patients with DLBCL achieve durable remissions with existing chemotherapies, the prognosis of patients with refractory DLBCL is poor. The immune landscape of DLBCL is complex and further elucidation of the interplay between T cell activation and immunosuppression within the tumor microenvironment (TME) is necessary in order to better stratify patients and predict outcomes for therapy. This complexity, as well as the relevance of the spatial context of the various cell types within the TME necessitate the ability to simultaneously visualize biomarkers and phenotypic markers via multiplex immunohistochemical (mIHC) assays.

Authors and institutions

Jennifer Ziello, Shuling Zhang, Sarah Klein, Tyler Levy, Derek Papalegis, Lily Vu, Gabriella Spang, Arvin Ruiz and Giorgio Inghirami
Cell Signaling Technology, Inc., Danvers MA 01923

Questions? We’re here to help.
Contact us
Categories: 26379 Masterclass Webinar Series:
A novel global phenotyping method using artificial intelligence to overcome the cell segmentation bottleneck
Resources / Masterclass Webinar Series:
A novel global phenotyping method using artificial intelligence to overcome the cell segmentation bottleneck
Phenoplex™
40:33 min
Rachel Baird (née Pennie), MSc
Masterclass Webinar Series: A novel global phenotyping method using artificial intelligence to overcome the cell segmentation bottleneck
Details
40:33 min
About the webinar

Multiplex methods for the detection of protein expression generate extremely data-rich images of intact tissue sections. These images are invaluable for the quantification and analysis of complex biology and have huge potential for biomarker development. However, their interpretation presents a considerable data analysis challenge which limits their utility, especially in clinical workflows.

The key task from these images is often cellular phenotyping – e.g. the identification of immunophenotypes, or the separation cells with compartment-specific protein expression from others. Most current automated methods depend upon a cellular segmentation step to support this, and segmentation has become an area of intensive research in AI (Artificial Intelligence), but the task is very difficult and no universally accepted method has been identified.

Therefore, methods of cellular phenotyping which operate without the need for segmentation would be very valuable. To meet this challenge, we have developed an AI cellular phenotyping method which does not require segmentation at all.

We use the U-Net backbone within the Visiopharm deep learning module to train our algorithm using expert human annotations of entire cellular regions. Crucially, we need only train for a single example of each compartmental stain (nuclear/cytoplasmic/membranous), and the algorithm then assigns class identities to cells without the need for segmentation of nuclei cytoplasm or membranes, using regional information in a manner analogous to a human expert, who may not need to be confident about cellular boundaries to accurately phenotype a cell.

The method is comparable in accuracy to segmentation-based methods, is highly transferrable, and represents a highly novel approach to quantitative image analysis with the potential to radically alter the way that we analyze these data-rich images.

Read the paper for more insights into the study

Expert

Rachel Baird (née Pennie), MSc

Rachel Baird, MSc is a translational histologist in the deep phenotyping advanced technology facility within the Le Quesne Lab at the CRUK Scotland Institute. She is an expert in the development and application of Visiopharm deep learning methods to multiplex and high plex histopathological images.

Questions? We’re here to help.
Contact us
Categories: 25859 Dissecting the myeloid compartment of the tumor microenvironment with SignalStar™ multiplex immunohistochemistry and Phenoplex image analysis
Resources / Dissecting the myeloid compartment of the tumor microenvironment with SignalStar™ multiplex immunohistochemistry and Phenoplex image analysis
Phenoplex™
Dissecting the myeloid compartment of the tumor microenvironment with SignalStar™ multiplex immunohistochemistry and Phenoplex image analysis
Originally presented at SITC 2024
Description

Myeloid cells, including macrophages, dendritic cells, monocytes, and granulocytes, are integral to the tumor microenvironment (TME). Recent multiomic technologies have identified distinct subpopulations of myeloid cells that regulate tumor progression and metastasis. Spatial biology technologies, such as multiplex immunohistochemistry (mIHC), are essential for investigating myeloid cell phenotype and function within the TME.

Authors and institutions

Sarah R Klein1, Lily Vu1, James Mansfield2, Fabian Schneider2

  1. Cell Signaling Technology, Inc., Danvers MA, USA
  2. Visiopharm A/S, Horsholm, Denmark
Questions? We’re here to help.
Contact us
Categories: 23932 A deep learning approach to guide acquisition region selection for imaging mass cytometry
Resources / A deep learning approach to guide acquisition region selection for imaging mass cytometry
Phenoplex™
A deep learning approach to guide acquisition region selection for imaging mass cytometry
Originally presented at SITC 2024
Description

The growth in cancer immunotherapy agents requires an understanding of the immune contexture of the tumor microenvironment (TME). This can be aided by high-plex imaging and analysis to obtain phenotypes of specific cells and study their biodistribution and interactions. Imaging Mass Cytometry (IMC) is the method of choice for single-step staining and high-plex imaging of tissues, avoiding the complications of autofluorescence and cyclic imaging.

IMC has expanded its capabilities with three distinct imaging modes: Preview, Cell, and Tissue. The Preview Mode  is a rapid scanning system that captures a comprehensive overview of the stained tissue, mapping out the distribution of over 40 markers and revealing tissue heterogeneity. This enables researchers to make informed decisions about which areas warrant closer examination on the same. Building on this, Cell Mode offers high-resolution imaging for detailed analysis of the Regions of Interest (ROIs) identified during Preview, all using the same slide. Tissue Mode complements these by providing a fast acquisition of the entire tissue at a lower resolution, which is optimal for quantitative pixel-based analysis of tissue biology. These modes support automated, continuous imaging of more than 40 large tissue samples (400 mm2) weekly. Following Preview Mode, the selection of ROIs for high-resolution imaging is a critical step, enhanced by automated AI algorithms to ensure it is informed by biomarker expression.

Authors

Smriti Kala1, Fabian Schneider2, Clinton Hupple1, James Mansfield2

  1. Standard BioTools Inc.
  2. Visiopharm A/S
Topics
Multimodal
Questions? We’re here to help.
Contact us
Categories: 25831 Fatty acid metabolism limits type I interferon responses in irradiated glioblastoma
Resources / Fatty acid metabolism limits type I interferon responses in irradiated glioblastoma
Phenoplex™
Fatty acid metabolism limits type I interferon responses in irradiated glioblastoma
Originally presented at SITC 2024
Description

Radiation therapy (RT) induces nucleic acid sensing followed by cancer cell-intrinsic interferon (IFN-I) responses in various cancers. However, combining RT with immunotherapy in glioblastoma has failed to improve patient survival, suggesting robust immunosuppression. Our previous findings showed that RT induces a metabolic shift towards fatty acid synthase (FASN)-mediated lipid synthesis, supporting glioblastoma survival (De Martino, et al. Cancer Lett. 2023). Since fatty acid metabolism hampers IFN-I responses in viral immunity, we hypothesized that FASN might similarly inhibit IFN-I in irradiated glioblastoma, acting as an immune evasion mechanism.

Authors and institutions

Mara De Martino1, Camille Daviaud1, María Cecilia Lira1, Matthew H. Ingalls2, Fabian Schneider3, Regan Baird3, James Mansfield3, J. Spencer Schwarz2, Oliver Braubach2 and Claire Vanpouille-Box1,4

  1. Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA
  2. Bruker Spatial Biology, Saint Louis, MO, USA
  3. Visiopharm A/S, Horsholm, Denmark
  4. Sandra and Edward Meyer Cancer Center, New York, NY, USA
Questions? We’re here to help.
Contact us
Categories:
Success
Your message has been successfully sent!